Description

Establishing a Passive Heymann Nephritis model requires an anti-Fx1A serum that matches the target animal, experimental design and intended level of disease severity. biofargo Bf-002S is a Sheep Anti-Rat Fx1A Serum supplied for the induction of Passive Heymann Nephritis in rats.

The product is supplied as 25 mL of Anti-Fx1A Serum in 0.02 M phosphate-buffered saline at pH 7.3. One package contains sufficient antibody for 25 rats weighing 175-200 g when used according to the stated directions. Male Sprague-Dawley rats are recommended, while other rat strains have not been tested.

Passive Heymann Nephritis production is dose-dependent. The complete antibody dose must be delivered, and differences between antiserum lots, rat sources and experimental requirements can affect the resulting disease severity. A dose-response study is therefore recommended for each lot before establishing the final experimental conditions.

The product data describe an initial heterologous phase followed by an autologous phase. Sheep IgG and rat C3 can localize in the glomerular capillaries, proteinuria can develop, and subepithelial immune deposits can be observed. The product has not been validated in mice, and chronic disease has not been verified using this Anti-Fx1A Serum.

Specification

biofargo Bf-002S Sheep Anti-Rat Fx1A Serum specifications
Parameter	Specification
Brand	biofargo
Catalog number	Bf-002S
Product name	Sheep Anti-Rat Fx1A Serum
Alternative name	Anti-Fx1A Serum
Product type	Antiserum
Host species	Sheep
Target species	Rat
Target	Fx1A
Application	Induction of Passive Heymann Nephritis
Form	Serum
Volume	25 mL
Buffer	0.02 M phosphate-buffered saline
pH	7.3
Storage	-20°C or below
Freeze-thaw instruction	Avoid repeated freeze-thaw cycles
Preparation before use	Centrifuge at 3,000 rpm
Animal coverage	Sufficient for 25 rats weighing 175-200 g when used according to the stated directions
Recommended rat strain	Male Sprague-Dawley rats
Other rat strains	Not tested
Mouse validation	Not validated in mice
Chronic disease verification	Chronic disease has not been verified using this Anti-Fx1A Serum

Features

Defined model application: Supplied for the induction of Passive Heymann Nephritis in rats.
Species-specific product: Sheep antiserum directed against rat Fx1A.
25 mL package: Contains sufficient antibody for 25 rats weighing 175-200 g when used according to the stated directions.
Specified formulation: Supplied in 0.02 M phosphate-buffered saline at pH 7.3.
Frozen storage: Store at -20°C or below and avoid repeated freeze-thaw cycles.
Pre-use preparation: Centrifuge the Anti-Fx1A Serum at 3,000 rpm before use.
Recommended animals: Male Sprague-Dawley rats are recommended.
Dose-dependent response: Complete delivery of the antibody dose is important for disease production.
Lot-specific study design: A dose-response study is recommended to establish the desired disease severity for each antiserum lot.

Application

biofargo Bf-002S Sheep Anti-Rat Fx1A Serum is supplied for the induction of Passive Heymann Nephritis in rats.

Passive Heymann Nephritis induction
Anti-Fx1A rat model establishment
Proteinuria assessment in the Passive Heymann Nephritis model
Glomerular sheep IgG deposition assessment
Glomerular rat C3 localization assessment
Subepithelial immune-deposit assessment
Glomerular basement membrane change assessment
Mesangial matrix change assessment

Heterologous Disease Phase

Faint to moderate deposits of heterologous sheep IgG can become detectable in the glomerular capillaries by immunofluorescence within minutes after a single administration of Anti-Fx1A Serum. The intensity and granularity of these deposits can increase during the following 3-5 days. Rat C3 can also localize in a granular pattern, and proteinuria can develop after approximately 5 days.

Autologous Disease Phase

The autologous phase can become noticeable 7-10 days after administration of the Anti-Fx1A antibody. The product data describe increased proteinuria and glomerular localization of rat IgG in a string-of-pearls pattern by immunohistochemistry. Subepithelial immune deposits can be observed by electron microscopy.

By approximately 3 weeks, proteinuria can reach 100-200 mg per 24 hours when measured using the Bradford assay. During the first few weeks, glomeruli may appear unremarkable by routine light microscopy. The data sheet describes possible progression to thickened basement membranes, increased mesangial matrix and possible sclerosis after approximately 3 months. Chronic disease, however, has not been verified using this Anti-Fx1A Serum.

FAQ

What is biofargo Bf-002S?

Bf-002S is a Sheep Anti-Rat Fx1A Serum supplied for the induction of Passive Heymann Nephritis in rats.

What is Sheep Anti-Rat Fx1A Serum used for?

The serum is used to induce a Passive Heymann Nephritis model in rats.

What is the catalog number of the Anti-Fx1A Serum?

The biofargo catalog number is Bf-002S.

What is the product volume?

Bf-002S is supplied as 25 mL of Anti-Fx1A Serum.

How many rats can be studied with one 25 mL package?

One package contains sufficient antibody to induce Passive Heymann Nephritis in 25 rats weighing 175-200 g when used according to the stated directions.

What rat strain is recommended?

Male Sprague-Dawley rats are recommended. Other rat strains were not tested in the referenced product data.

Can Bf-002S Anti-Fx1A Serum be used in mice?

The product has not been validated in mice.

What buffer is used for Bf-002S?

The Anti-Fx1A Serum is supplied in 0.02 M phosphate-buffered saline at pH 7.3.

How should the Anti-Fx1A Serum be stored?

Store the serum at -20°C or below and avoid repeated freeze-thaw cycles.

Does the serum require preparation before use?

Yes. The product data instruct users to centrifuge the serum at 3,000 rpm before use.

What is the stated dose for Passive Heymann Nephritis induction?

The stated dose is 0.4 mL of Anti-Fx1A Serum per 100 g of body weight.

How is the serum administered according to the data sheet?

The data sheet describes administration into a tail vein over a period of 15-30 seconds after the rat has been anesthetized.

Why is complete dose delivery important?

Passive Heymann Nephritis production is dose-dependent. The product data state that the complete antibody dose must be delivered.

Why is a dose-response study recommended?

Antiserum lots, rat sources and experimental requirements can vary. A dose-response study is recommended to establish the desired disease severity for each lot.

When can proteinuria develop in the Passive Heymann Nephritis model?

The product data state that proteinuria can develop after approximately 5 days during the heterologous phase. By approximately 3 weeks, proteinuria can reach 100-200 mg per 24 hours when measured using the Bradford assay.

What immune-deposit pattern is described in the autologous phase?

Rat IgG can localize in the glomeruli in a string-of-pearls pattern by immunohistochemistry. Subepithelial immune deposits can also be observed by electron microscopy.

Has chronic Passive Heymann Nephritis been verified with Bf-002S?

No. Chronic disease has not been verified using this Anti-Fx1A Serum.